Document is current
Any future updates will be listed below
-
Authors
Kang, Min Kyu
Song, Jeong Eun
Loomba, Rohit
Park, Soo Young
Tak, Won Young
Kweon, Young Oh
Lee, Yu Rim
Park, Jung Gil
-
Funding
Funding for this research was provided by:
2023 Yeungnam University Research Grant (223A061030)
NCATS (5UL1TR001442)
NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318,, P30DK120515)
NHLBI (P01HL14783)
John C Martin Foundation (RP124)
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 25 September 2024
First Online: 2 October 2024
Declarations
:
: RL serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.
: This study was approved by the Institutional Review Board (IRB) of the Yeungnam University Hospital (IRB No. 2023-11-026) and performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Owing to the retrospective nature of this study, the requirement for written informed consent was waived.
